- Home
- EXAS vs LEGN Comparison
EXAS vs LEGN Comparison
Compare EXAS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- LEGN
- Stock Information
- Founded
- EXAS 1995
- LEGN 2014
- Country
- EXAS United States
- LEGN United States
- Employees
- EXAS N/A
- LEGN N/A
- Industry
- EXAS Medical Specialities
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EXAS Health Care
- LEGN Health Care
- Exchange
- EXAS Nasdaq
- LEGN Nasdaq
- Market Cap
- EXAS 12.3B
- LEGN 9.1B
- IPO Year
- EXAS N/A
- LEGN 2020
- Fundamental
- Price
- EXAS $71.05
- LEGN $45.57
- Analyst Decision
- EXAS Strong Buy
- LEGN Strong Buy
- Analyst Count
- EXAS 13
- LEGN 13
- Target Price
- EXAS $79.00
- LEGN $81.46
- AVG Volume (30 Days)
- EXAS 1.4M
- LEGN 1.3M
- Earning Date
- EXAS 11-05-2024
- LEGN 11-12-2024
- Dividend Yield
- EXAS N/A
- LEGN N/A
- EPS Growth
- EXAS N/A
- LEGN N/A
- EPS
- EXAS N/A
- LEGN N/A
- Revenue
- EXAS $2,612,011,000.00
- LEGN $455,991,000.00
- Revenue This Year
- EXAS $15.53
- LEGN $108.95
- Revenue Next Year
- EXAS $13.78
- LEGN $81.26
- P/E Ratio
- EXAS N/A
- LEGN N/A
- Revenue Growth
- EXAS 13.54
- LEGN 176.93
- 52 Week Low
- EXAS $40.62
- LEGN $38.60
- 52 Week High
- EXAS $79.62
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- EXAS 55.81
- LEGN 44.41
- Support Level
- EXAS $68.61
- LEGN $44.56
- Resistance Level
- EXAS $71.49
- LEGN $46.15
- Average True Range (ATR)
- EXAS 1.91
- LEGN 2.05
- MACD
- EXAS -0.34
- LEGN 0.19
- Stochastic Oscillator
- EXAS 50.41
- LEGN 33.83
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.